Skip to content

Study · Randomized controlled trial · 2017

7 results

A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.

King AB, Philis-Tsimikas A, Kilpatrick ES, Langbakke IH, Begtrup K, Vilsbøll T

Diabetes technology & therapeutics10 Mar 2017Cited by 18 (Europe PMC)

PMID28282219 (opens in a new tab)PMCIDPMC5399738 (opens in a new tab)DOI10.1089/dia.2016.0405 (opens in a new tab)PepBankPUB-28282219
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira (insulin degludec plus liraglutide) gave a greater proportion of SMBG values within target ranges than insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, adding liraglutide to insulin degludec put more blood glucose readings in the target range than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion of SMBG values within target range, IDegLira versus IDeg
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with IDeg, IDegLira resulted in a greater proportion of subjects with SMBG values within target ranges (3.9-9.0 mmol/L) than IDeg for all pre- and postprandial values, and for the full nine-point profile (P < 0.05 for all).
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira reduced the 24-hour range of SMBG values more than insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, adding liraglutide to insulin degludec narrowed the daily swing in blood glucose more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseRange of SMBG values over 24 h, IDegLira versus IDeg
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    IDegLira also resulted in a greater reduction in the range of SMBG values over 24 h than IDeg (P ≤ 0.0001).
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira reduced interstitial glucose fluctuation more than insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, adding liraglutide to insulin degludec reduced glucose swings on continuous monitoring more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseInterstitial glucose fluctuation (CGM), IDegLira versus IDeg
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CGM data showed that IDegLira provided greater reductions in interstitial glucose (IG) fluctuation (P = 0.0018) and postprandial IG increment (P = 0.0288) compared with IDeg.
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira reduced the postprandial interstitial glucose increment more than insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, adding liraglutide to insulin degludec reduced the rise in glucose after meals more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial interstitial glucose increment (CGM), IDegLira versus IDeg
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    CGM data showed that IDegLira provided greater reductions in interstitial glucose (IG) fluctuation (P = 0.0018) and postprandial IG increment (P = 0.0288) compared with IDeg.
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira gave a higher proportion of SMBG values within target ranges than liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the insulin degludec and liraglutide combination put more blood glucose readings in the target range than liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion of SMBG values within target range, IDegLira versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with liraglutide, IDegLira brought a higher proportion of subjects within SMBG target ranges (all pre- and all postprandial values, and the full nine-point profile, P < 0.01 for all) and resulted in a greater reduction of time outside the IG target range (P = 0.0072).
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira reduced time outside the interstitial glucose target range more than liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the insulin degludec and liraglutide combination cut time out of the glucose target range more than liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseTime outside interstitial glucose target range, IDegLira versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with liraglutide, IDegLira brought a higher proportion of subjects within SMBG target ranges (all pre- and all postprandial values, and the full nine-point profile, P < 0.01 for all) and resulted in a greater reduction of time outside the IG target range (P = 0.0072).
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira reduced mean interstitial glucose more than liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the insulin degludec and liraglutide combination lowered average glucose more than liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean interstitial glucose, IDegLira versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    IDegLira also reduced mean IG more than liraglutide (P < 0.0001).
    1 context sentence
    Summary · context
    We analyzed nine-point self-monitored blood glucose (SMBG) profiles from two randomized trials involving IDegLira in patients with type 2 diabetes (T2D), and continuous glucose monitoring (CGM) data from a subset of patients in one of these trials to assess glycemic fluctuation and day-to-day variability.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01392573

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 41328 Nov 2011 to 4 Oct 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 3 Jan 2019
CompletedPhase 3Results postedNCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,66323 May 2011 to 22 Nov 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 19 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.